

Title (en)
Vpr AND Vpx PROTEINS OF HIV

Title (de)
DIE VPR- UND VPX-PROTEINE DES HIV

Title (fr)
PROTEINES Vpr ET Vpx DU VIH

Publication
EP 0753006 A4 19990414 (EN)

Application
EP 95912976 A 19950324

Priority
• AU 9500169 W 19950324
• AU PM469794 A 19940325
• AU PN090295 A 19950203

Abstract (en)
[origin: WO9526361A1] This invention relates to a biologically active peptide fragment of the Vpr protein of human immunodeficiency virus, to pharmaceutical compositions comprising these peptides or biologically active analogues thereof, to antagonists of the peptides, and to pharmaceutical compositions comprising these antagonists and to therapeutic and screening methods utilising compounds and compositions of the invention. In one preferred embodiment, the invention provides an antagonist of the Vpr protein of human immunodeficiency virus (HIV), or of a biologically active fragment or analogue thereof, comprising at least one amino acid sequence motif selected from HFRIG and HSRIG which has the ability to inhibit one or more activities mediated by Vpr, selected from the group consisting of growth arrest, cell replication arrest, cytotoxicity, cytoskeletal disruption, and effects on the endoplasmic reticulum. The invention also relates to use of Vpr protein, or a biologically active fragment or analogue thereof comprising the consensus sequence, in treatment of conditions mediated by cellular proliferation or caused by eukaryotic pathogens.

IPC 1-7
C07K 7/06; C07K 7/08; C07K 14/155; C07K 14/16; C07K 16/10; C07H 21/04; C12N 15/63; C12N 15/48; C12Q 1/02; A61K 39/21; A61K 39/42

IPC 8 full level
C12N 15/09 (2006.01); **A61K 35/76** (2006.01); **A61K 38/00** (2006.01); **A61K 39/395** (2006.01); **A61K 48/00** (2006.01); **A61P 31/04** (2006.01); **A61P 31/12** (2006.01); **A61P 35/00** (2006.01); **A61P 35/02** (2006.01); **A61P 37/04** (2006.01); **A61P 43/00** (2006.01); **C07H 21/04** (2006.01); **C07K 7/06** (2006.01); **C07K 7/08** (2006.01); **C07K 14/155** (2006.01); **C07K 14/16** (2006.01); **C12N 15/00** (2006.01); **C12P 21/02** (2006.01); **C12P 21/08** (2006.01); **C12Q 1/02** (2006.01); **A61K 39/00** (2006.01); **C12R 1/865** (2006.01); **C12R 1/92** (2006.01)

CPC (source: EP)
A61P 31/04 (2018.01); **A61P 31/12** (2018.01); **A61P 35/00** (2018.01); **A61P 35/02** (2018.01); **A61P 37/04** (2018.01); **A61P 43/00** (2018.01); **C07K 14/005** (2013.01); **A61K 38/00** (2013.01); **A61K 39/00** (2013.01); **C12N 2740/16322** (2013.01)

Citation (search report)
• [X] WO 9015875 A1 19901227 - DANA FARBER CANCER INST INC [US]
• [PX] WO 9419456 A1 19940901 - WEINER DAVID B [US], et al
• [T] ZHANG S ET AL: "Direct binding to nucleic acids by Vpr of human immunodeficiency virus type 1", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, vol. 212, no. 2, 8 June 1998 (1998-06-08), pages 157-166, XP004122917
• [A] COHEN E A ET AL.: "Identification of HIV-1 vpr product and function", JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, vol. 3, no. 1, 1990, new york, pages 11 - 18, XP002085625
• See also references of WO 9526361A1

Designated contracting state (EPC)
DE FR GB IT

DOCDB simple family (publication)
WO 9526361 A1 19951005; CA 2186398 A1 19951005; EP 0753006 A1 19970115; EP 0753006 A4 19990414; JP H09511395 A 19971118

DOCDB simple family (application)
AU 9500169 W 19950324; CA 2186398 A 19950324; EP 95912976 A 19950324; JP 52487095 A 19950324